Glecaprevir / Pibrentasvir (4) – Maviret®

Name: Frühe Nutzenbewertungen nach § 35a SGB V
Creator: Gemeinsamer Bundesausschuss

Acute hepatitis C virus infection, ≥ 3 years

Start date	01.08.2026
Resolution	21.01.2027 – active procedure
INN	Glecaprevir/Pibrentasvir
Brand name	Maviret®
Pharm. company	AbbVie Deutschland GmbH & Co. KG
G-BA Procedure ID	D-1355
Therapeutic area	Infectious diseases
Reason for procedure	New therapeutic indication

active procedures repealed resolutions


01.08.2026	21.01.2027	Glecaprevir / Pibrentasvir (4)	Maviret®	AbbVie Deutschland GmbH & Co. KG	Infectious diseases	Acute hepatitis C virus infection, ≥ 3 years	n.d.	active procedure
01.07.2021	16.12.2021	Glecaprevir / Pibrentasvir (3)	Maviret®	AbbVie Deutschland GmbH & Co. KG	Infectious diseases	Chronic hepatitis C, 3 to < 12 years	146–238	100% additional benefit not proven
15.04.2019	17.10.2019	Glecaprevir / Pibrentasvir (2)	Maviret®	AbbVie Deutschland GmbH & Co. KG	Infectious diseases	Chronic hepatitis C, 12 to < 18 years	540	100% additional benefit not proven
01.08.2017	01.02.2018	Glecaprevir / Pibrentasvir (1)	Maviret®	AbbVie Deutschland GmbH & Co. KG	Infectious diseases	Chronic hepatitis C	104,600	100% additional benefit not proven

<< List of all resolutions